× Home Screening and diagnosis of type 2 diabetesGlycaemic monitoring and targets for type 2 diabetesLifestyle managementNon-insulin medicationsInsulinScreening and management of complications of diabetesManagement of cardiovascular risk factors in diabetesManagement of hypoglycaemiaSick day managementDiabetes in pregnancyDiabetes and drivingPrediabetesGo to the NZSSD site

Type 2 Diabetes Management Guidelines

GLP-1 receptor agonists (GLP1RA)

New Special Authority Criteria for dulaglutide and liraglutide – please click here for more information.


  • Special Authority Criteria
  • Patient has type 2 diabetes with an HbA1c > 53 mmol/mol despite at least 3 months of regular use of metformin and/or an alternative glucose lowering therapy, not on a funded SGLT2i (i.e. empagliflozin) AND any of the following:
    • Diabetic renal disease (urinary albumin:creatinine ratio > 3 mg/mmol and/or eGFR < 60 mL/min) OR
    • Known cardiovascular disease (any ischaemic heart disease, cerebrovascular event, peripheral vascular disease, congestive heart failure or familial hypercholesterolaemia) OR
    • 5 year cardiovascular disease risk > 15% OR
    • A high lifetime cardiovascular risk due to onset of diabetes in childhood or as a young adult OR
    • Māori or Pacific ethnicity

More reading...

Unapproved medicines and unapproved uses of medicines: keeping prescribers and patients safe